Organon & Co. (OGN)
| Market Cap | 3.50B |
| Revenue (ttm) | 6.22B |
| Net Income (ttm) | 187.00M |
| Shares Out | 262.60M |
| EPS (ttm) | 0.72 |
| PE Ratio | 18.50 |
| Forward PE | 3.86 |
| Dividend | $0.08 (0.60%) |
| Ex-Dividend Date | Feb 23, 2026 |
| Volume | 36,737,242 |
| Open | 13.19 |
| Previous Close | 13.16 |
| Day's Range | 13.18 - 13.38 |
| 52-Week Range | 5.69 - 13.38 |
| Beta | 0.64 |
| Analysts | Sell |
| Price Target | 10.75 (-19.29%) |
| Earnings Date | May 7, 2026 |
About OGN
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote develo... [Read more]
Financial Performance
In 2025, Organon & Co.'s revenue was $6.22 billion, a decrease of -2.92% compared to the previous year's $6.40 billion. Earnings were $187.00 million, a decrease of -78.36%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for OGN stock is "Sell." The 12-month stock price target is $10.75, which is a decrease of -19.29% from the latest price.
News
Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Organon & Co. (NYSE: OGN) breached their ...
Organon Stock Soars After Sun Seals Takeover. Why Pharma M&A Is a Hot Play.
India's Sun Pharmaceutical Industries agrees to buy the women's health company for $14 a share in an all-cash deal.
Why is Sun Pharma betting $11.75B on a struggling US drugmaker?
In one of the biggest outbound acquisitions ever attempted by an Indian company, Sun Pharmaceutical Industries has decided to buy Organon & Co. for $14 a share in an all-cash deal valued at $11.8 bill...
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion. Sun Pharmaceutical will buy all outstanding shares of Organ...
Sun Pharmaceutical to Acquire Organon Valued at $11.75 Billion
India's Sun Pharmaceutical Industries 524715 -3.57%decrease; red down pointing triangle has agreed to acquire U.S.-listed healthcare company Organon OGN 30.93%increase; green up pointing triangle & Co...
Sun Pharma to acquire Organon in $11.75 bln all-cash deal
Sun Pharmaceutical Industries will acquire Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion, the companies said in a joint statement on Sunday.
Sun Pharma signs Definitive Agreement to Acquire Organon
MUMBAI, India & JERSEY CITY, N.J.--(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or asso...
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will release its first quarter 2026 financial results and host conference call on May 7, 2026.
Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
JERSEY CITY, N.J.--(BUSINESS WIRE)--VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.
Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet
Citing people familiar with the matter, the Economic Times reported that Sun Pharma has completed an extensive due diligence process spanning more than three months.
This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring.
Organon stock jumped after a report said Sun Pharmaceutical Industries is nearing an all-cash deal for the women's health company.
This Women's Healthcare Stock Is Up 15% on Reports of a Takeover In the Works
Organon shares are popping Friday on signs of a takeover deal.
These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More.
Lumentum and Coherent were gaining on signs of strong artificial-intelligence hardware demand, while Organon was boosted by a takeover report.
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients.
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potent...
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS
STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (P...
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has ...
Organon & Co. Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA for 2025 were $6.2B and $1.9B, respectively, with biosimilars and new product launches offsetting headwinds from loss of exclusivity and policy changes. 2026 guidance is flat, with continued cost discipline, margin pressure, and deleveraging focus.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.
Organon Completes Divestiture of JADA® System to Laborie
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company.
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs.
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.